Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 8, 2008

View Archived Issues

Significant treatment effect seen with gepirone ER in depression studies

Link between metabotropic glutamate receptor and fragile X syndrome seen in mice

Brain cholesterol reduction with LXR agonist beneficial in experimental Niemman-Pick disease

Recent patents report novel anticancer agents

BioMarin and Genzyme restructure their joint venture for Aldurazyme for MPS I

Novel therapeutic compounds for metabolic disorders described in recent patent literature

Innocoll initiates dosing in U.S. phase II clinical trial of CollaRx bupivacaine surgical implant

Multifunctional serotonin receptor modulator suppresses psychosis and appetite in mice

Astellas Pharma reports third quarter 2007 results

Recent patents disclose new psychopharmacologic drugs

Pfizer and Taisho sign definitive agreement for novel schizophrenia drug candidate

Access acquires Somanta and adds four new anticancer compounds to pipeline

Biogen and Elan report on Tysabri safety in MS patients

Celldex receives fast track designation for glioblastoma vaccine CDX-110

Jazz Pharmaceuticals receives orphan drug designation for acute repetitive seizures candidate

Optimer awarded NIH grant to develop OPT-80 for hospital-associated infection

Orphan drug designation granted for non-radiolabeled TM-601

Sangamo initiates phase II clinical trial of SB-509 in diabetic neuropathy

Metabasis reports positive results from phase Ib clinical trial of MB-07811 for hyperlipidemia

R-7128 achieves rapid virologic response in 4-week combination study for HCV

Rib-X initiates two phase II studies of oxazolidinone antibiotic RX-1741 for CAP and uSSSI

Callisto restructures license agreement with Genzyme for atiprimod for carcinoid cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...